United Therapeutics Corporation (UTHR)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $25.18B
Last updated: Nov 17, 2026 at 11:06 AM ET
United Therapeutics Corporation (UTHR) Financials: Revenue, Profit and Cash Flow
United Therapeutics reported revenue of $3.18B for the fiscal year ended Dec 31, 2025, up 10.6% from the year before. That year, net income was $1.33B with a net margin of 41.9%, operating cash flow was $1.56B and free cash flow was $1.04B. The quarter ended Sep 30, 2026 had revenue of $832.50M and net income of $258.60M.
Revenue and Margins
The operating margin was 46.9% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.60B, a compound annual rate of 7.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $3.18B | +10.6% | 87.9% | 46.9% | 41.9% |
| Dec 2024 | $2.88B | +23.6% | 89.2% | 47.9% | 41.5% |
| Dec 2023 | $2.33B | +20.2% | 88.9% | 50.9% | 42.3% |
| Dec 2022 | $1.94B | +14.9% | 92.2% | 50.6% | 37.6% |
| Dec 2021 | $1.69B | +13.6% | 92.7% | 33.0% | 28.2% |
| Dec 2020 | $1.48B | +2.4% | 92.7% | 40.0% | 34.7% |
| Dec 2019 | $1.45B | -11.0% | 91.9% | -12.9% | -7.2% |
| Dec 2018 | $1.63B | -5.7% | 87.8% | 49.5% | 36.2% |
| Dec 2017 | $1.73B | +7.9% | 93.9% | 47.2% | 24.2% |
| Dec 2016 | $1.60B | N/A | 95.5% | 66.4% | 44.6% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 10.8% from the year before. In the quarter ended Sep 2026, net income fell 23.6% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B | $1.48B | $1.45B | $1.63B | $1.73B | $1.60B |
| Cost of revenue | $384.40M | $309.70M | $257.50M | $151.60M | $122.50M | $108.10M | $117.60M | $198.70M | $105.70M | $72.70M |
| Gross profit | $2.80B | $2.57B | $2.07B | $1.78B | $1.56B | $1.38B | $1.33B | $1.43B | $1.62B | $1.53B |
| Research and development | $550.00M | $481.00M | $408.00M | $322.90M | $540.10M | $357.70M | $1.18B | $357.90M | $264.60M | $147.60M |
| Operating income | $1.49B | $1.38B | $1.18B | $979.70M | $555.90M | $593.60M | -$187.60M | $805.40M | $814.90M | $1.06B |
| Net income | $1.33B | $1.20B | $984.80M | $727.30M | $475.80M | $514.80M | -$104.50M | $589.20M | $417.90M | $713.70M |
| EBITDA | $1.63B | $1.46B | $1.22B | $989.10M | $648.00M | $692.80M | -$119.10M | N/A | N/A | $1.09B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $832.50M | $783.30M | $781.50M | $790.20M | $799.50M | $798.60M | $794.40M | $735.90M | $748.90M | $714.90M | $677.70M | $614.70M |
| Gross profit | $733.40M | $683.80M | $648.10M | $686.80M | $698.60M | $711.00M | $701.90M | $660.00M | $665.80M | $637.10M | $604.80M | $543.70M |
| Operating income | $307.80M | $330.80M | $325.80M | $356.70M | $388.50M | $364.50M | $382.80M | $357.70M | $343.10M | $319.90M | $356.30M | $260.10M |
| Net income | $258.60M | $333.00M | $274.90M | $364.30M | $338.70M | $309.50M | $322.20M | $301.30M | $309.10M | $278.10M | $306.60M | $217.10M |
Balance Sheet
As of Dec 2025, cash and equivalents of $1.56B were 19.8% of total assets of $7.88B, against total liabilities of $783.80M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.88B | $7.36B | $7.17B | $6.04B | $5.17B | $4.62B | $3.91B | $3.40B | $2.88B | $2.33B |
| Current assets | $3.70B | $3.87B | $3.55B | $3.38B | $2.32B | $2.17B | $1.86B | $1.77B | $1.45B | $1.42B |
| Cash and equivalents | $1.56B | $1.70B | $1.21B | $961.20M | $894.80M | $738.70M | $738.40M | $669.20M | $705.10M | $1.02B |
| Total liabilities | $783.80M | $920.00M | $1.18B | $1.25B | $1.21B | $1.22B | $1.13B | $593.20M | $758.40M | $463.40M |
| Short-term debt | N/A | $300.00M | $400.00M | $0 | N/A | N/A | $250.00M | N/A | $250.00M | N/A |
| Long-term debt | N/A | N/A | $300.00M | $800.00M | $800.00M | $800.00M | $600.00M | $250.00M | $250.00M | $0 |
| Shareholder equity | $7.10B | $6.44B | $5.98B | $4.80B | $3.96B | $3.40B | $2.78B | $2.79B | $2.10B | $1.85B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.03B | $7.22B | $6.71B | $7.88B | $7.35B | $7.91B | $7.74B | $7.36B | $7.12B | $6.72B | $6.50B | $7.17B |
| Total liabilities | $758.10M | $819.80M | $813.10M | $783.80M | $760.90M | $734.40M | $936.70M | $920.00M | $1.02B | $1.03B | $1.16B | $1.18B |
| Cash and equivalents | $1.19B | $1.80B | $1.28B | $1.56B | $1.34B | $1.59B | $1.90B | $1.70B | $1.55B | $1.36B | $1.25B | $1.21B |
| Shareholder equity | $6.28B | $6.40B | $5.90B | $7.10B | $6.59B | $7.17B | $6.81B | $6.44B | $6.10B | $5.70B | $5.34B | $5.98B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 66.7% of operating cash flow. Share repurchases came to 96.2% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.56B | $1.33B | $978.00M | $802.50M | $598.20M | $755.70M | -$206.60M | $778.40M | $474.20M | $643.60M |
| Capital expenditures | $520.50M | $246.50M | $230.40M | $138.80M | $120.80M | $59.30M | $83.70M | $184.40M | $86.30M | $38.00M |
| Free cash flow | $1.04B | $1.08B | $747.60M | $663.70M | $477.40M | $696.40M | -$290.30M | $594.00M | $387.90M | $605.60M |
| Dividends paid | N/A | N/A | $98.00M | $94.30M | N/A | $38.50M | $14.00M | N/A | $0 | $7.70M |
| Share repurchases | $1.00B | $1.00B | $0 | $0 | N/A | N/A | N/A | N/A | $250.00M | $500.00M |
| Investing cash flow | -$551.30M | $417.20M | -$719.60M | -$811.50M | -$486.90M | -$738.50M | -$335.40M | -$820.60M | -$835.60M | $48.30M |
| Financing cash flow | -$1.15B | -$1.25B | -$11.90M | $75.40M | $44.80M | -$16.90M | $611.20M | $6.30M | $43.30M | -$497.70M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $306.50M | $313.60M | $463.30M | $346.20M | $562.10M | $191.70M | $461.20M | $341.20M | $377.20M | $232.20M | $376.50M | $150.70M |
| Capital expenditures | $180.70M | $108.00M | $100.80M | $172.90M | $210.50M | $62.20M | $74.90M | $86.70M | $76.50M | $45.10M | $38.20M | $78.70M |
| Free cash flow | $125.80M | $205.60M | $362.50M | $173.30M | $351.60M | $129.50M | $386.30M | $254.50M | $300.70M | $187.10M | $338.30M | $72.00M |
Frequently Asked Questions About UTHR
What is United Therapeutics' annual revenue?
United Therapeutics reported revenue of $3.18B for the fiscal year ended Dec 31, 2025.
How fast is United Therapeutics' revenue growing?
Revenue was up 10.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 18.0%.
Is United Therapeutics profitable?
Yes. United Therapeutics reported net income of $1.33B for the fiscal year ended Dec 31, 2025, with a net margin of 41.9%.
How much free cash flow does UTHR generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.56B minus capital expenditures of $520.50M produced free cash flow of $1.04B.
How much debt does United Therapeutics have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $1.56B.
UTHR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts